Nasdaq Stockholm’s listing committee has approved Xbrane Biopharma ABs (Xbrane) application to admit Xbrane's shares to trading on Nasdaq Stockholm Main Market.

The first day of trading of Xbrane’s shares on Nasdaq Stockholm will be Monday 23 September 2019.

Xbrane is a commercial phase Swedish biopharmaceutical company that develops, manufactures and produces biosimilars.

Vator Securities is financial adviser and Baker McKenzie is legal adviser to Xbrane in connection with the change of listing venue. Baker McKenzie’s team consists of Joakim Falkner, Henric Roth, Johanna Flink and Olof Larsson.

Explore Our Newsroom